Cardiometabolic Integration: From Molecular and Cellular Networks to Therapeutic Targets (J6)
January 23-27, 2028
| Fairmont Banff Springs, Banff, AB, Canada
Carolyn L. Cummins, Stephan Herzig and Judith Altarejos
| 1:00–6:00 PM |
Registration |
|
| 3:00–3:10 PM |
Welcome Remarks |
|
| 3:10–4:00 PM |
Keynote Address |
|
| |
Sekar Kathiresan †, Verve Therapeutics
Building the Future of Cardiometabolic Therapeutics |
|
| 4:00–6:00 PM |
Cardiometabolic Crossroads, Converging Biology (Joint) |
|
| |
Naveed Sattar †, University of Glasgow
Diabetic Cardiomyopathy and HFpEF: Emerging Mechanisms and Clinical Endpoints |
|
| |
Philipp E. Scherer †, University of Texas Southwestern Medical Center
Adipose Tissue as an Endocrine Organ in Health and Disease |
|
| |
Carolyn L. Cummins, University of Toronto
Novel LXR Targets at the Heart of Cardiometabolic Disease |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:00–8:00 PM |
Welcome Reception |
|
Tuesday, January 25, 2028
| 8:00–11:15 AM |
Precision Medicine to Improve Cardiometabolic Health |
|
| |
Sanjiv Shah †, Northwestern University
Precision Subtyping of HFpEF for Better Treatments |
|
| |
Barry A. Borlaug †, Mayo Clinic
Type 2 Diabetes, Obesity and CKD as Convergent Drivers in HFpEF |
|
| |
Judith Altarejos, Regeneron Pharmaaceuticals Inc.
Translating Combination Approaches to Improve Cardiometabolic Health |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
|
| 11:25–12:25 PM |
Panel Discussion 1: Reproducibility Challenges- Standardization of Pre-Clinical Models |
|
| 12:25–1:30 PM |
Poster Setup |
|
| 12:25–5:00 PM |
On Own for Lunch |
|
| 1:30–10:00 PM |
Poster Viewing |
|
| 2:30–4:30 PM |
Symposia Spotlight 1: Heart failure and Diabetic Cardiomyopathy |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
MASLD, MASH, and Cardiovascular Disease: New Concepts to Guide Therapies |
|
| |
Francois Pattou †, Lille University
Subtype Analysis of MASLD Patients Reveals Differential Susceptibility to CVD |
|
| |
Ira Tabas †, Columbia University
Defective Macrophage Efferocytosis Links MASH and Atherosclerosis |
|
| |
Isabelle Leclercq †, Université catholique de Louvain
Cardiac Remodeling in Mouse MASH Models |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
Wednesday, January 26, 2028
| 8:00–11:00 AM |
Inter-Organ Messengers and Their Cardiometabolic Targets |
|
| |
Stephan Herzig, Helmholtz Zentrum München
Linking Hepatokines and Heart Function in Cachexia |
|
| |
Kerstin Stemmer †, University of Augsburg
Exosomes as Therapeutic Modalities in Metabolic Disease |
|
| |
Kacey J. Prentice †, University of Toronto
NDPK a Cardiometabolic Adipokine, Regulates Energy Homeostasis |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–1:00 PM |
Poster Setup |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 3:00–4:30 PM |
Career Roundtable |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Epigenetic and Hormonal Regulation of the Diabetic Heart |
|
| |
Adam R. Wende †, University of Alabama at Birmingham
Nutrient-Driven Epigenetic Remodeling in the Diabetic Heart |
|
| |
Erin E. Mulvihill †, University of Ottawa
Type 2 diabetes, Menopause, and Increased Risk of Heart Disease |
|
| |
Andrea L. Hevener †, University of California, Los Angeles
ERα as a Guardian of Cardiometabolic Health |
|
| |
Johannes Backs †, University of Heidelberg
HDACs as Therapeutic Targets in Cardiac Health and Disease |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
Thursday, January 27, 2028
| 8:00–11:00 AM |
Mitochondria and Metabolites in Cardiometabolic Diseases |
|
| |
Jessica B. Spinelli †, University of Massachusetts Chan Medical School
Functional Specialization of Mitochondria in Cells: Not all Mitochondria are Created Equal! |
|
| |
Phillip White †, Duke University
BCAAs Contribute to Energy Partitioning in NASH |
|
| |
Jared Rutter †, University of Utah
Mitochondrial Messengers in Metabolic Health and Disease |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:10–12:10 PM |
Panel Discussion 2: AI Integration Across Drug Discovery – Basic to Clinical |
|
| 12:10–5:00 PM |
On Own for Lunch |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: Novel Molecular Mediators of Inter-Organ Crosstalk |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–6:45 PM |
Genetics-Driven Trial Enrichment and Target Validation (Joint) |
|
| |
Mark I. McCarthy, Genentech
From Human Genetics to Clinical Translation |
|
| |
Anthony Andrew Philippakis †, Google Ventures
AI and the Future of Therapeutics |
|
| |
Pradeep Natarajan †, Amgen
Polygenic Risk Scores for Trial Enrichment in Cardiovascular and Metabolic Disease |
|
| |
Beryl Cummings †, Marea Therapeutics
ANGPTL4 as a Validated Cardiometabolic Target: From Population Genetics to the Clinic |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions |
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 PM |
Entertainment |
|
